O'Shaughnessy Asset Management’s Intellia Therapeutics NTLA Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,180	Closed	-$231K	–	1328
2022 Q1	$231K	Sell	3,180 -475	-13%	-$40.2K	﹤0.01%	1013
2021 Q4	$432K	Sell	3,655 -3	-0.1%	-$376	0.01%	739
2021 Q3	$492K	Buy	3,658 +841	+30%	+$127K	0.01%	653
2021 Q2	$456K	Sell	2,817 -131	-4%	-$10.2K	0.01%	696
2021 Q1	$236K	Sell	2,948 -59	-2%	-$3.96K	0.01%	862
2020 Q4	$164K	Buy	+3,007	New	+$109K	﹤0.01%	903

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

O'Shaughnessy Asset Management's NTLA Position: Q2 2022 in Review

O'Shaughnessy Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 3,180 shares — an estimated $231K sold.

O'Shaughnessy Asset Management first reported a position in NTLA in Q4 2020 and held it in 6 quarters. The position peaked at $492K in Q3 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

O'Shaughnessy Asset Management reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
O'Shaughnessy Asset Management sold 3,180 Intellia Therapeutics shares in Q2 2022, an estimated $231K.
O'Shaughnessy Asset Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 6 quarters.
O'Shaughnessy Asset Management's Intellia Therapeutics position peaked at $492K in Q3 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.